GLP-1 Drugs Are Becoming More Than Weight Loss Medicine
Tirzepatide just earned an approval that has nothing to do with the scale. Here is what SELECT, FLOW and the new sleep apnea data show.
Jan 8, 2025

Search
10 stories for“weight loss”
Tirzepatide just earned an approval that has nothing to do with the scale. Here is what SELECT, FLOW and the new sleep apnea data show.
Jan 8, 2025

Semaglutide and tirzepatide went from diabetes treatment to celebrity shortcut to a genuine health story. What happens when one drug becomes a cultural moment.
Apr 20, 2024

The biggest head-to-head diet trial ever run found near-identical weight loss. The real variable turned out to be the person, not the macro.
Nov 18, 2024

Trial data on stopping semaglutide shows most of the lost weight comes back within a year. Here is what the STEP 1 extension found.
May 15, 2024

A major Cochrane review of nearly 2,000 people found intermittent fasting barely beats ordinary dieting. Here is what the data really supports.
Mar 10, 2026

Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024

Shortages pushed patients toward compounded semaglutide. The FDA's latest alert shows why that workaround carries real risk.
Aug 5, 2024

Berberine lowers cholesterol and blood sugar in small trials, but comparing it to semaglutide misreads both the data and the biology.
Feb 14, 2024

Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026

GLP-1 receptor agonists did not start as weight loss drugs. Here is the biology behind Ozempic, Mounjaro and the hormone they mimic.
Jan 25, 2024
